The development of new drugs by a deep-sea enterprise brings double happiness, giving new hope to Alzheimer's disease patients.

Recently, Shenzhen Boree Jian Pharmaceutical Co., Ltd. announced that its independently developed innovative drug BrAD-R13 for the treatment of Alzheimer's disease type 1 has successfully completed Phase I clinical trials. The trial validated the safety and pharmacokinetic properties of the drug in human subjects for the first time, bringing new hope to millions of patients worldwide. Yesterday, it was learned from the Longgang District Science and Technology Bureau that recent significant progress has been made in the research and development of innovative drugs by Scihi Pharmaceutical (Shenzhen) New Drug Research Center Co., Ltd. in the district. The new drug is expected to provide a new treatment strategy for patients with immune diseases such as rheumatoid arthritis and systemic lupus erythematosus. (Shenzhen Special Zone Daily)